OCT 31, 2018 02:46 PM PDT

New Drug Target For a Rare Lymphoma

WRITTEN BY: Nouran Amin

The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the McGill University Health Centre (RI-MUHC), the Montreal Children's Hospital of the MUHC (MCH-MUHC), and McGill University in collaboration with French teams from AP-HP, Inserm, Université Paris-Descartes and the Imagine Institute at the Necker-Enfants Malades Hospital, have shed new light on a molecule called TIM-3 which may be implicated in the regulation of immune responses.

Credit: McGill University Health Centre via MedicalXpress.com

Tenzin Gayden (co-first author) in Dr. Jabado's laboratory at the Research Institute of the McGill University Health Centre in Montreal. -MedicalXpress

“The results of this collaboration demonstrate the regulatory role of the TIM-3 molecule in humans and they also provide strong arguments for reconsidering this entity as an inflammatory rather than a malignant pathology, and for promoting the use of immunosuppressive drugs in its treatment," explains Dr. Geneviève de Saint Basile.

According to the study published in journal Nature Genetics, the researchers have identified TIM-3 as a potential target for immunotherapeutic treatments in patients with cancer and other diseases. Specifically, they found that when the protein is under suppression, then immune responses become out of control and overly-activated leading to subcutaneous panniculitis T lymphoma (LTSCP), a rare form of lymphoma that starts in the lymphocytes.

Watch this short video below to learn more about Lymphoma:

They found that two forms of mutations at the origin of this syndrome that target TIM-3 protein, inhibiting it from expression on the surface of lymphocytes (T-cells)--attacking the cancer cells, thus, serving as a potential drug target. "The discovery of this mutation has shed light on a previously undescribed mechanism that allowed us to explain both the clinical presentation and the very particular evolution of these lymphomas under treatment," explains Dr. David Michonneau from the hematology-transplant service in the Saint-Louis AP-HP hospital.

The mutations have also been found in individuals of East Asian, Australian, and Polynesian origin as well as in patients of European origin. "For these patients with this rare form of lymphoma, our results reinforce the use of immunosuppressive therapies that will provide much better results and fewer side effects than cytotoxic chemotherapy," states Dr. Nada Jabado, professor of Pediatrics and Human Genetics at McGill University in Montreal.

Researchers are hopeful to use their study to see if a drug target, where TIM-3 is implicated, can help patients with other autoimmune diseases such as lupus, infectious diseases such as HIV or even malaria and multiple sclerosis.

Source: McGill University Health Centre

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 16, 2018
Neuroscience
OCT 16, 2018
Your brain tells if a placebo can treat pain
Placebo effect and predicting when a particular subject will have a placebo response by using as little as psychological questionnaires....
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Potential Targeted Treatment for Crohn Disease
Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract. Now,...
NOV 30, 2018
Immunology
NOV 30, 2018
Aspirin May Impove MS Symptoms
The medical benefits of aspirin have been known since ancient times. Hippocrates, c. 400 BC, prescribed the salicylate-rich bark and leaves of the willow t...
DEC 18, 2018
Drug Discovery
DEC 18, 2018
Increasing Misuse of Prescription Drugs
According to a study published in Psychiatric Services in Advance, misuse of prescription drugs accounts for more than 17 percent of overall use. In the st...
DEC 26, 2018
Drug Discovery
DEC 26, 2018
Novel Water Approach May Improve Drug Design
An understanding of the basic molecular properties of water greatly influences drug design. But, a significant comprehension of water interactions and its ...
FEB 08, 2019
Drug Discovery
FEB 08, 2019
Apsirin Use Prevents Colorectal Cancer
In a study published in the American Journal of Medicine, the U.S. Preventive Services Task Force (USPSTF) concluded that aspirin use decreases the risk of...
Loading Comments...